Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in bladder...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )
30 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Comment: Enfortumab vedotin is an effective therapy and important development fo...
Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak
Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )
18 Jun 2019
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for...
Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )
13 Jun 2019
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
NILE: Should we give everything to patients with unresectable locally advanced o...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer? ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemo...
Prof Thomas Flaig - University of Colorado Denver, Denver, USA
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )
10 Jun 2019
Genetic testing and PARP inhibitors in metastatic prostate cancer
Dr Neal Shore and Dr Joaquin Mateo
Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )
7 Jun 2019
Metastatic castration resistant prostate cancer: Updates from ASCO 2019
Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi
Metastatic castration resistant prostate cancer: Updates from ASCO 2019 ( Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi )
7 Jun 2019